DS
TCRR

David Shaw’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

David Shaw’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-155,495
Closed -$280K – 5303
2022
Q3 		$280K Sell
155,495
-423,392
-73% -$1.23M ﹤0.01% 4330
2022
Q2 		$1.68M Sell
578,887
-223,620
-28% -$552K ﹤0.01% 3216
2022
Q1 		$2.21M Buy
802,507
+358,750
+81% +$1.13M ﹤0.01% 3195
2021
Q4 		$2.07M Buy
+443,757
New +$2.77M ﹤0.01% 3325
2021
Q3 		– Sell
-55,350
Closed -$908K – 5377
2021
Q2 		$908K Sell
55,350
-33,040
-37% -$667K ﹤0.01% 3620
2021
Q1 		$1.95M Buy
+88,390
New +$2.41M ﹤0.01% 2612

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

David Shaw's TCRR Position: Q4 2022 in Review

David Shaw sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 155,495 shares — an estimated $280K sold.

David Shaw first reported a position in TCRR in Q1 2021 and held it in 6 quarters. The position peaked at $2.21M in Q1 2022. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • David Shaw reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • David Shaw sold 155,495 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $280K.
  • David Shaw first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • David Shaw's TCR2 Therapeutics Inc. Common Stock position peaked at $2.21M in Q1 2022.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.